Insights On Outsourced Drug Development
-
An Integrated Analytical Approach To Lipase Risk Management In Biologics Development
9/8/2026
Conventional HCP testing cannot confirm whether residual lipases remain enzymatically active. Here, the authors examine why functional activity data are essential for managing polysorbate-related stability risk in biologics development.
-
Doubling Up For Speed In Biomanufacturing
12/12/2025
Accelerate drug development and reduce risk with parallel operations. Learn how leveraging CDMO partnerships while building internal capabilities can cut costs and speed your path to market.
-
Ask Us Anything: Päivi Tolstoy On The Future Of API Manufacturing
7/23/2026
Päivi Tolstoy, Manager of Process Development at Cambrex Karlskoga, on why sustainability is the trend to watch in API manufacturing — and why the real question is how few steps it takes to build a complex molecule.
-
Optimizing Particle Properties For Difficult Small Molecules
11/3/2026
Crystal morphology and unexpected solid-state intermediates often decide whether a difficult small molecule filters, dries, and scales. Thermodynamic stability may not be the right target.
-
Small Molecule Orphan Drugs: Status Quo, Challenges, And Perspectives
3/11/2026
By establishing robust manufacturing processes and scalable production strategies from the outset, developers can help de-risk orphan drug production, improve efficiency, and position their programs for greater long-term success.
-
Ask Us Anything: Daniele Vigo On Cost-Effective Process Development
7/23/2026
Daniele Vigo, Assistant Director at Cambrex Milan, on getting yield, purity, and scalability right without burning through the budget.
-
Lipid Nanoparticles For Pulmonary Delivery Of mRNA
7/1/2026
Gain insight into how nebulized mRNA lipid nanoparticles show preclinical success in lung delivery, offering fresh momentum for inhaled gene therapies targeting respiratory diseases.
-
Nanomedicine Modalities Find Path To Clinic Through Analytics
5/16/2025
Lipid nanoparticles have revolutionized drug delivery, ushering in a new era of nanomedicine. Discover how advanced analytical tools are accelerating next-generation LNP therapeutics.
-
Why Controlled Release Is Essential For Patient-centric Drug Development
10/15/2026
Controlled release design can ease daily dosing burden by moderating swings in drug exposure, though the right approach depends on API properties and what manufacturing can deliver at scale.
-
Advancing Next Gen Antibodies: From AI Driven CLD To Manufacturing
6/2/2026
See how growing ADC complexity is driving the adoption of AI-enabled, data-driven CMC strategies that accelerate development, improve product insight, and strengthen manufacturing readiness.